BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 17 2025
0mins
Should l Buy ?
Source: PRnewswire
Delisting from Nasdaq: BrainStorm Cell Therapeutics has received a notification of delisting from the Nasdaq Stock Market due to non-compliance with minimum shareholder equity requirements, effective July 18, 2025. The company will transition to trading on the OTCQB Venture Market under the same symbol, BCLI.
Commitment to ALS Research: Despite the delisting, CEO Chaim Lebovits reassured stakeholders that the company's mission to advance its NurOwn therapy for ALS remains unchanged, emphasizing ongoing research and development efforts, including preparations for a pivotal Phase 3b trial with the FDA.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
